Bavarian Nordic and its partners conduct clinical studies of its vaccine candidates to evaluate their safety and efficacy.
Clinical studies that are actively enrolling patients or are planned are detailed below.
Cancer immunotherapy product candidates
|PROSTVAC||Phase 1/2 Study of PROSTVAC in Combination With Nivolumab and / or Ipilimumab in Men With Prostate Cancer||USA||NCT02933255|
|PROSTVAC||Phase 2 Trial of PROSTVAC and Ipilimumab as Monotherapy or in Combination for Men With Localized Prostate Cancer Undergoing Radical Prostatectomy||USA||NCT02506114|
|PROSTVAC||Phase 2 Randomized, Placebo-Controlled Trial of PROSTVAC in Patients With Clinically Localized Prostate Cancer Undergoing Active Surveillance||USA||NCT02326805|
|PROSTVAC||Phase 2 Study of PROSTVAC in Patients With Biochemical Recurrent Prostate Cancer||USA||NCT02649439|
|PROSTVAC||Phase 2 Study of PROSTVAC and Docetaxel for Metastatic Castration Sensitive Prostate Cancer||USA||NCT02649855|
|CV301||Phase 1/2 Trial of CV301 in Combination With Nivolumab Versus Nivolumab in Subjects With Previously Treated Non-Small Cell Lung Cancer||USA||NCT02840994|
|CV301||Phase 2 Study Combining CV301 (PANVAC) with Bacillus Calmette-Guerin (BCG) vs. BCG Alone in High Grade Non-Muscle Invasive Bladder Cancer||USA||NCT02015104|
Infectious disease product candidates
|MVA-BN Filo||Phase 2 study evaluating the safety, tolerability and immunogenicity of MVA-BN Filo and Ad26.ZEBOV administered in different sequences and schedules in healthy adult participants.||United Kingdom/
|MVA-BN Filo||Phase 2 study evaluating the safety, tolerability and immunogenicity of three prime-boost regimens of MVA-BN Filo and Ad26.ZEBOV in healthy adult participants, including elderly, HIV-infected, and healthy children in three age strata.||Uganda/
|MVA-BN Filo||Phase 3 study evaluating the safety and immunogenicity of Ebola candidate vaccines Ad26.ZEBOV and MVA-BN-Filo (EBOVAC-Salone)||Sierra Leone||NCT02509494|
|MVA-BN YF||Phase 1 Trial to Evaluate the Safety, Reactogenicity, and Immunogenicity of MVA-BN Yellow Fever Vaccine With and Without Montanide ISA-720 Adjuvant in 18-45 Year Old Healthy Volunteers||USA||NCT02743455|